Status:
COMPLETED
Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
Lead Sponsor:
Prescott Woodruff
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Asthma
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response...
Eligibility Criteria
Inclusion
- Allergic/Non-Asthmatic subjects and Allergic/Asthmatic subjects
- Positive skin test to dust mite or cat allergen
- Non-Allergic/Non-Asthmatic subjects
- Negative skin test to panel of 12 allergens, including dust mite and cat allergen
- All groups
Exclusion
- History of intubation for asthma exacerbation
- Use of Xolair (omalizumab) within the last 6 months
- Immunotherapy with cat or dust mite extract now or in the past 5 years
- ≥ 10 pack-years smoking or any smoking in the past year
- Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection
- History of dermatographia
- History of anaphylaxis to cat allergen
- Participation in another research study involving a drug or biologic during the past 30 days
- Presence of past or current medical problems/other factors that may pose additional risks from participation or influence study results, as determined per study investigator
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT02230189
Start Date
March 1 2015
End Date
January 1 2020
Last Update
August 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143